knowledge -WSS

knowledge

author：entertainment 2025-09-30 23:11:11 - browse：346

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： New Alzheimer's drugs heat up race for early detection blood tests

WSS

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

NVIDIA and Google execs on the future of AI and drug discovery

What it's like to live with paralysis for one psychologist

When prostate cancer spreads, where it goes matters

Second House panel advances two

HIV vaccine remains elusive. Immunologists keep trying new ideas

Wikipedia

knowledge

leisure time

Supreme Court strikes down use of affirmative action

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Wildfire smoke exposes gaps in outdoor worker protections

Biden warns of ‘dark winter’ during final presidental debate

How one medical school became remarkably diverse

Senate panel puts off hardest PBM reforms for another day

Activists slam private health insurers over coverage restrictions

Dems pitch expanding Medicare power to negotiate drug prices

Medical records are filled with copy

Will the FTC rein in IQVIA's health data empire?

focus

HIV vaccine remains elusive. Immunologists keep trying new ideas

Military medical care influenced by rank and race, new study finds

Dems pitch expanding Medicare power to negotiate drug prices

Addiction experts warn against a second 'war on drugs'

What it's like to live with paralysis for one psychologist

CDC Director Mandy Cohen on transparency, trust, and health

leisure time

explore

entertainment

explore